Victory Square Technologies Inc. announced that its over 3,000 nurses, 107 white-label locations and their patients now have access to Tirzepatide through the Hydreight platform and its associated Medical network in over 700 cities across 50 states in the United States. Tirzepatide is an FDA-approved medicine used to treat type 2 diabetes mellitus and may be used off-label for the treatment of obesity due to its effective weight loss qualities. It functions as a dual GLP-1 and GIP agonist.

Similar to other GLP-1 medicines, it is currently used as a second-line diabetic treatment and administered as a once-weekly subcutaneous injection. Tirzepatide is in the same product line as Semaglutide, which Hydreight launched at the end of 2023. Tirzepatide and Semaglutide injections are commonly used to treat type 2 diabetes.

It can also be used together with diet and exercise to help control blood sugar and has become popular to help with weight management. Tirzepatide and Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and is only available with a doctor?s prescription and needs to be injected on a regular basis. Since the beginning of the year, the Company has seen significant growth and increased demand for its Semaglutide offering.

Between January and February, there was a 250%+ increase in the number of Semaglutide orders. Semaglutide is injected on a monthly basis, and due to the recurring nature, the Company expects to see continued monthly growth. Obesity, characterized by abnormal or excessive fat accumulation that poses risks to both physical and mental health, has nearly tripled worldwide since 1975, according to the World Health Organization (WHO).

Currently, it ranks as the fifth-leading risk factor for mortality globally. Factors such as dietary habits, physical activity levels, and genetics contribute to the rising obesity rates, which are expected to continue increasing. According to the World Obesity Atlas 2023, if current trends persist, over half of the global population will be overweight or obese by 2035, compared to 38% in 2020.

The Company?s product offering aims to include various products and category options to ensure the customers? needs are met. Hydreight is adding higher priced products that need to be taken on an ongoing basis, which is more lucrative for the nurses.

Every time a product is added, nurses must go through extensive training and onboarding to ensure the product is administered safely and correctly All these products allow healthcare providers using the Hydreight platform to provide a higher level of medicine and provide a pathway to shift into medical essentials.